呼吸抑制(Respiratory Depression)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Respiratory Depression Overview 6
Therapeutics Development 7
Pipeline Products for Respiratory Depression – Overview 7
Pipeline Products for Respiratory Depression – Comparative Analysis 8
Respiratory Depression – Therapeutics under Development by Companies 9
Respiratory Depression – Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Respiratory Depression – Products under Development by Companies 12
Respiratory Depression – Companies Involved in Therapeutics Development 13
Cortex Pharmaceuticals, Inc. 13
Galleon Pharmaceuticals 14
Respiratory Depression – Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 23
CX-1739 – Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CX-1942 – Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CX-2007 – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CX-2076 – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
doxapram hydrochloride – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
GAL-021 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
GAL-021 Successors – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
tianeptine – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Respiratory Depression – Recent Pipeline Updates 32
Respiratory Depression – Dormant Projects 35
Respiratory Depression – Product Development Milestones 36
Featured News & Press Releases 36
Sep 24, 2014: Cortex Pharmaceuticals Announces Phase 1 Funding by the National Institute of Drug Abuse, National Institutes of Health, Under the Small Business Innovation Research Funding Award Program 36
Feb 12, 2014: Revive Therapeutics Announces Encouraging Interim Results from Ongoing Phase 2a Proof-Of-Concept Study of REV-001 for the Prevention of Opioid-Induced Respiratory Depression 36
Sep 20, 2012: Galleon Pharma Reports Positive Results From Second Phase I Study Of GAL-021 For Treatment Of Respiratory Depression 37
May 07, 2012: Galleon Reports Positive Results From Phase I Study Of GAL-021 For Treatment Of Respiratory Depression 38
Aug 24, 2011: Cortex Receives US Patent For Use Of Ampakine Molecules To Treat Respiratory Depression 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41